Navigation Links
Morelli receives AACR fellowship for research in metastatic colorectal cancer
Date:4/15/2013

The University of Texas MD Anderson Cancer Center, accepted the one-year, $50,000 grant at the AACR Annual Meeting 2013 grants reception and dinner. The award is one of six granted to MD Anderson researchers and faculty at the meeting.

The Fight Colorectal Cancer-AACR Fellowship, in memory of Lisa Dubow, represents a joint effort to encourage and support a postdoctoral or clinical research fellow conducting translational or clinical research on therapeutic approaches for late stage colorectal cancer. The grant supports a project designed to lead to individualized treatment options for patients.

Colorectal cancer is the fourth common cancer diagnosed in the United States each year. The National Cancer Institute estimates 142,820 new cases of colon or rectal cancer bill be diagnosed in 2013, and 50,830 patients will die of the disease.

Over the last decade, the development of anti-epidermal growth factor receptor monoclonal antibodies, such as cetuximab and panitumumab, has improved the clinical outcomes in metastatic colorectal cancer patients who don't have KRAS mutations. Yet, not all of these select patients obtain clinical benefits, and refinement of the predictive biomarker is necessary, says Scott Kopetz, M.D., Ph.D., associate professor in MD Anderson's Department of Gastrointestinal Medical Oncology.

"A patient's tumor is composed of many variations of always-changing cancer cells," said Kopetz, Morelli's mentor. "Standard methods don't capture the current state of the cancer at the time that treatment is started. With recently developed techniques, the patient's blood can provide an increasingly transparent window into the current inter-workings of the cell, allowing better selection of chemotherapy treatments."

Morelli's project will aim to answer specific clinical research questions relevant to the biology of colorectal cancer, and provide insights that may advance the care of patients in the near future.

"Specifically, we will focus on two critical aspects of tumor biology that are anticipated to have profound clinical outcomes: the recognition that both tumor heterogeneity and the acquired mutations in KRAS and EGFR play a substantial role in determining resistance to chemotherapy," Morelli said.

Lisa Dubow was 42 years old when she was diagnosed with Stage III colorectal cancer, which later recurred. A founder of the Fight Colorectal Cancer, Dubow also worked for the "Lisa Fund," which supports researchers and is dedicated to improving therapies and outcomes for patients with late-stage disease.


'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. The Law Office of Wolf & Pravato, The Alters Firm and Morelli Ratner File Class Action Lawsuit Against Global Spray Foam Manufacturer
2. Christopher Jayne, M.D., Receives InTone Specialist Certification To Treat Female Urinary Incontinence From InControl Medical, LLC
3. Local Female Clinical Research Executive Receives Industry Distinction as an Innovator for Change
4. Tosh Patterson Receives Honors at the 5th Annual Get RADICAL Women’s Conference Featuring Jillian Michaels, Lisa Nichols, Giuliana Rancic
5. Vincent R. Lucente, MD, MBA, Miles Murphy, MD, Nina Bhatia, MD, and Valerie Schissler, MSN, CRNP, Receives InTone Specialist Certification
6. Advanced Mold Diagnostics Receives Angie's List Super Service Award for 4th Straight Year
7. BU student receives 2013 Joanna M. Nicolay Melanoma Foundation scholarship award
8. UC Davis MIND Institute receives prestigious Autism Centers of Excellence Award
9. Citel’s Portico™ TVA™ Receives Updated Validation from BroadSoft
10. Kessler Foundation scientist receives National MS Society grant for predictors of memory decline
11. Port Washington, NY Dentist Dr. Doron Keren of Gold Coast Family Dental Receives 98 Percent Satisfaction Rating from Patient Reviews
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... A new report released today ... end-to-end sleep health care at scale, indicates record-breaking adherence results for the company’s ... positive airway pressure (PAP) therapy, the most widely utilized treatment for OSA, typically ...
(Date:7/24/2017)... , ... July 24, 2017 , ... Summer storms are ... wreak havoc across communities and often result in massive tree damage requiring emergency tree ... can take now including tree trimming, tree cabling and hazardous tree removal. ...
(Date:7/24/2017)... ... ... interactive Bible study guide for children. “The Perfect Gift” is the creation of published author, ... as her Savior, yet never studied His word, surrendered to His will, or served Him ... her children, so they would know the importance of the truth. She is honored ...
(Date:7/23/2017)... ... July 24, 2017 , ... Three ... in Medicine (AAPM) 59th Annual Meeting & Exhibition, to be held in Denver, ... profession, hospital administrators and journalists can visit the AAPM Facebook page to watch ...
(Date:7/23/2017)... ... July 23, 2017 , ... Specializing in one sport early in a child’s ... or even go on to the pros. However, researchers presenting their work at the ... say “not so fast.” , “Our study, which is the largest study to ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... -- Wolfmet 3D  printed tungsten collimator manufactured by M&I Materials proves ... to progress molecular radiotherapy imaging. In molecular radiotherapy ... accurately quantify the radiation absorbed by those patients undergoing treatment. ... this radiotherapy treatment has been available — that is, until ... ...
(Date:7/1/2017)... June 30, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... earnings conference call will be broadcast live over the Internet ... A news release detailing the quarterly results will be made ... conference call. The live audio webcast can be ... . It will be archived for replay following the conference ...
(Date:6/27/2017)... TEL AVIV, Israel , June 27, 2017 /PRNewswire/ ... a specialty clinical-stage pharmaceutical company specializing in the development ... ring The Nasdaq Stock Market Opening Bell in ... 28, 2017 in honor of its initial public offering ... Nasdaq Capital Market in March 2017. Dr. ...
Breaking Medicine Technology: